Freespira Overview

  • Founded
  • 2013
Founded
  • Status
  • Private
  • Employees
  • 30
Employees
  • Latest Deal Type
  • Series D
  • Latest Deal Amount
  • $10M
Latest Deal Amount
  • Investors
  • 8

Freespira General Information

Description

Freespira, Inc. is the maker of Freespira, the only FDA-cleared digital therapeutic proven to significantly reduce or eliminate symptoms of panic attacks, panic disorder, and post-traumatic stress disorder (PTSD) in just 28 days by training users to normalize respiratory irregularities.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Clinics/Outpatient Services
Primary Office
  • 12020 113th Avenue Northeast
  • Suite 215
  • Kirkland, WA 98034
  • United States
+1 (800) 000-0000

Freespira Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Freespira Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series D) 16-Oct-2020 $10M 000.00 0000 Completed Generating Revenue
5. Later Stage VC (Series C) 12-Apr-2019 00.000 000.00 000.00 Completed Generating Revenue
4. Early Stage VC (Series B) 03-Mar-2016 00.000 00.00 000.00 Completed Generating Revenue
3. Early Stage VC (Series B) 09-Mar-2015 00.000 00.000 000.00 Completed Generating Revenue
2. Early Stage VC (Series A1) 23-Jun-2014 $1.25M $2.25M 00.00 Completed Generating Revenue
1. Early Stage VC (Series A) 02-Oct-2013 $1M $1M 00.000 Completed Startup
To view Freespira’s complete valuation and funding history, request access »

Freespira Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series C 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series B 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A1 1,927,706 $0.001000 $0.05 $0.62 $0.62 1x $0.62 3.4%
Series A 5,000,000 $0.001000 $0.02 $0.2 $0.2 1x $0.2 8.82%
To view Freespira’s complete cap table history, request access »

Freespira Executive Team (9)

Name Title Board Seat Contact Info
Dean Sawyer Chief Executive Officer & Board Member
Simon Thomas President & Chief Operating Officer
Robert Cuyler Ph.D Chief Clinical Officer
Joseph Perekupka Chief Commercial Officer
You’re viewing 4 of 9 executive team members. Get the full list »

Freespira Board Members (7)

Name Representing Role Since
Dean Sawyer Freespira Chief Executive Officer & Board Member 000 0000
Debra Reisenthel Freespira Board Member 000 0000
Edwin Scheetz Aphelion Capital Board Member 000 0000
Jonathan MacQuitty Ph.D Lightspeed Venture Partners Board Member 000 0000
Russell Siegelman Freespira Chairman 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Freespira Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Freespira Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Lightspeed Venture Partners Venture Capital Minority 000 0000 000000 0
Medvest Capital Venture Capital Minority 000 0000 000000 0
Vesalius Ventures Venture Capital Minority 000 0000 000000 0
Aphelion Capital Venture Capital Minority 000 0000 000000 0
Farzad Nazem Angel (individual) Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »